A simple skin swab test for Parkinson's disease, inspired by a retired nurse who could smell the condition on her husband, is moving toward clinical trials after researchers at the University of Manchester identified a distinctive chemical signature in the skin's oils.
The story begins with Joy Milne, a former nurse who has hyperosmia, a heightened sensitivity to smell. She noticed a change in the scent of her husband Les years before he was diagnosed with Parkinson's. "It went from a fairly standard musky-man smell to something stronger and mustier," she recalled, according to the University of Manchester. Les was diagnosed with Parkinson's around 12 years later.
Milne later attended a talk by Professor Tilo Kunath, a regenerative neurobiologist at the University of Edinburgh, and asked why researchers weren't investigating the distinct odour she associated with Parkinson's. Kunath contacted his collaborator, Professor Perdita Barran, a mass spectrometry specialist at the University of Manchester. "It sounded so extraordinary I didn't know what to think," Barran said, according to the university. "We tested Joy and she really could smell Parkinson's."
Currently, there is no clinically established molecular test for Parkinson's. The UK's NICE diagnostic referral pathway relies on movement indicators, but the disease can manifest more than 40 symptoms. By the time motor symptoms are pronounced enough for a referral, up to 70% of the brain's dopamine-producing nerve cells may have already been lost, according to the university. Seeing a specialist, the only route to an official diagnosis, can then take many months.
The Manchester team reasoned that Milne might be detecting metabolic changes that precede motor symptoms. In an initial study, people with Parkinson's and healthy controls wore T-shirts that Milne assessed without seeing the participants. She correctly identified the Parkinson's T-shirts and noted the odour was strongest in sebum-rich areas like the back of the neck and between the shoulders. Sebum is the oily substance that protects skin from drying out. Remarkably, she also identified a T-shirt from the control group as having the Parkinson's odour — that individual was later diagnosed with Parkinson's.
Using mass spectrometry, a technique that weighs molecules precisely to identify and quantify them, the researchers discovered the molecules responsible. They collaborated with Professor Monty Silverdale, a neurologist at Salford Royal, who helped secure ethical approval for a clinical trial backed by £50,000 from Parkinson's UK, and later with support from the Michael J. Fox Foundation.
The trial focused on molecular signals collected via simple skin swabs. PhD student Eleanor Sinclair developed methods to extract and measure the molecules, while postdoctoral researcher Drupad Trivedi analysed the data. Together they identified a distinct chemical signature of Parkinson's, including changes in lipid metabolism and essential amino acids. Using a simple skin swab, the team can detect around 15,000 molecular features, approximately 10% of which consistently differ in abundance between people with and without Parkinson's.
The team has now sampled more than 7,000 participants worldwide, consistently detecting the Parkinson's signature across different ages, ethnicities and sampling locations, according to the university. The biomarkers also change as the disease progresses, raising the possibility of using them both for diagnosis and to monitor progression.
The research has led to a spin-out company, SebOMIX, which is seeking investment for a trial in Greater Manchester. The trial would sample around 400 people with suspected Parkinson's, referred by their GPs, and another roughly 400 people with other symptoms such as dementia. The team at the Manchester Institute of Biotechnology would work with clinical biochemists at Wythenshawe Hospital to analyse the swabs without knowing which was which. If the clinical laboratory can reproduce the research findings, the team will use the results to support regulatory approval and laboratory accreditation processes involving the MHRA and UKAS.
The hope is that a swab could help decide who should be referred to a Parkinson's-only clinic, where patients can receive targeted care from a range of specialists, easing pressure on waiting lists. If chemical changes can be found before movement symptoms appear, it might also help identify people who could take part in trials of treatments that aim to protect nerve cells.
For Barran, who leads the Michael Barber Centre for Collaborative Mass Spectrometry at the MIB, the ultimate goal is clear. "We now want to translate this lab-based diagnostic into something that can be used routinely in clinic to diagnose and better understand this awful condition," she said, according to the university.
Joy Milne continues to contribute to Parkinson's research, working with Parkinson's UK on training for health and care staff, and with Drupad Trivedi and the Defence Science and Technology Laboratory to understand hyperosmia. She hopes her extraordinary sense of smell will ultimately improve diagnosis and treatment for people with Parkinson's.